{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T04:33:07Z","timestamp":1783053187975,"version":"3.54.6"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["NCT04908475"],"award-info":[{"award-number":["NCT04908475"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Treatment of psoriasis with risankizumab has demonstrated superior efficacy to other treatments, such as adalimumab, ustekinumab and secukinumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study compared the efficacy and safety of risankizumab and apremilast in adults with moderate plaque psoriasis eligible for systemic therapy. It also evaluated the efficacy and safety of switching to risankizumab vs. continuing apremilast in patients who did not achieve \u2265 75% improvement in Psoriasis Area and Severity Index (PASI 75 nonresponders) after 16 weeks of treatment with apremilast.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This 52-week, phase IV, multicentre, randomized, open-label, efficacy assessor-blinded study (NCT04908475) enrolled patients (aged\u00a0\u2265\u00a018\u2005years) with a diagnosis of moderate chronic plaque psoriasis (\u2265 6\u2005months) and who were candidates for systemic therapy. The enrolled patients (randomized 1 : 2) received subcutaneous risankizumab (150\u2005mg at weeks 0 and 4) or oral apremilast (30\u2005mg twice daily). At week 16, all patients treated with apremilast were re-randomized (1 : 1) to risankizumab or apremilast, stratified by week-16 PASI 75 response. The co-primary outcomes in period A at week 16 were the achievement of \u2265 90% improvement in Psoriasis Area and Severity Index (PASI 90) and static Physician\u2019s Global Assessment (sPGA) 0\/1 with a two-grade or better improvement from baseline. At week 52, the primary endpoint in period B was the achievement of PASI 90 in PASI 75 nonresponders with apremilast at week 16. Safety was monitored throughout the study. All patients who received one dose of treatment were included in the efficacy and safety analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At baseline, 118 and 234 patients were assigned to receive risankizumab and apremilast, respectively. At week 16, PASI 90 was achieved by 55.9% [95% confidence interval (CI) 47.0\u201364.9] and 5.1% (95% CI 2.3\u20138.0), and sPGA 0\/1 by 75.4% (95% CI 67.7\u201383.2) and 18.4% (95% CI 13.4\u201323.3), respectively. In period B, among PASI 75 nonresponders with apremilast at week 16, 83 switched to risankizumab and 78 continued apremilast. At week 52, 72.3% (95% CI 62.7\u201381.9) who switched to risankizumab achieved PASI 90 vs. 2.6% (95% CI 0.0\u20136.1) who continued apremilast. The most frequent adverse events (reported in \u2265 5%) in risankizumab-treated patients were COVID-19 infection and nasopharyngitis. Diarrhoea, nausea and headache were most frequent among apremilast-treated patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>For patients with moderate psoriasis, treatment with risankizumab demonstrated superior efficacy to those treated with apremilast, including those who did not benefit from prior treatment with apremilast. The safety profile of risankizumab was similar to prior studies, and no new safety signals were identified. These results show that, compared with apremilast, risankizumab treatment can significantly improve clinical outcomes in systemic-eligible patients with moderate psoriasis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljad252","type":"journal-article","created":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T17:22:35Z","timestamp":1689873755000},"page":"540-552","source":"Crossref","is-referenced-by-count":19,"title":["Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse)"],"prefix":"10.1093","volume":"189","author":[{"given":"Linda F","family":"Stein Gold","sequence":"first","affiliation":[{"name":"Department of Dermatology, Henry Ford Hospital , Detroit, MI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Bagel","sequence":"additional","affiliation":[{"name":"Psoriasis Treatment Center of New Jersey , East Windsor, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen K","family":"Tyring","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Microbiology and Molecular Genetics and Internal Medicine, The University of Texas Medical School at Houston , Houston, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H Chih-ho","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Skin Science, University of British Columbia , Vancouver, BC ,","place":["Canada"]},{"name":"Probity Medical Research , Surrey, BC ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lev","family":"Pavlovsky","sequence":"additional","affiliation":[{"name":"Tel Aviv University , Tel Aviv ,","place":["Israel"]},{"name":"Rabin Medical Centre , Petah Tikva ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2624-2724","authenticated-orcid":false,"given":"Ronald","family":"Vender","sequence":"additional","affiliation":[{"name":"Dermatrials Research , Hamilton, ON ,","place":["Canada"]},{"name":"Venderm Consulting , Hamilton, ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Pinter","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Frankfurt am Main , Frankfurt am Main ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Reich","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Institute of Medical Sciences, Medical College of Rzesz\u00f3w University , Rzesz\u00f3w ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonidas","family":"Drogaris","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianshuang","family":"Wu","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Patel","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M","family":"Soliman","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huzefa","family":"Photowala","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassilis","family":"Stakias","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Richter","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9557-3642","authenticated-orcid":false,"given":"Kim A","family":"Papp","sequence":"additional","affiliation":[{"name":"Probity Medical Research and Alliance Clinical Trials , Waterloo, ON ,","place":["USA"]},{"name":"Division of Dermatology,\u00a0Department of Medicine, University of Toronto , Toronto, ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,25]]},"reference":[{"key":"2026041404120121900_ljad252-B1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jaut.2015.07.008","article-title":"The immunogenetics of\u00a0psoriasis: a comprehensive review","volume":"64","author":"Harden","year":"2015","journal-title":"J Autoimmun"},{"key":"2026041404120121900_ljad252-B2","author":"World Health Organization"},{"key":"2026041404120121900_ljad252-B3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s13555-018-0279-5","article-title":"Clinical goals and barriers to effective psoriasis care","volume":"9","author":"Strober","year":"2019","journal-title":"Dermatology Ther"},{"key":"2026041404120121900_ljad252-B4","first-page":"504","article-title":"The challenge of managing psoriasis: unmet medical needs and stakeholder perspectives","volume":"9","author":"Feldman","year":"2016","journal-title":"Am Health Drug Benefits"},{"key":"2026041404120121900_ljad252-B5","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/bjd.18333","article-title":"Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register,\u00a0BADBIR)","volume":"182","author":"Mahil","year":"2020","journal-title":"Br J Dermatol"},{"key":"2026041404120121900_ljad252-B6","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1111\/jdv.16568","article-title":"A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL)","volume":"34","author":"Seneschal","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026041404120121900_ljad252-B7","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jamadermatol.2013.5264","article-title":"Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation Surveys, 2003\u20132011","volume":"149","author":"Armstrong","year":"2013","journal-title":"JAMA Dermatol"},{"key":"2026041404120121900_ljad252-B8","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/jdv.14868","article-title":"Shifting the focus \u2013 the primary role of IL-23 in psoriasis and other inflammatory disorders","volume":"32","author":"Gooderham","year":"2018","journal-title":"J Eur Acad Dermatol"},{"key":"2026041404120121900_ljad252-B9","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis","volume":"201","author":"Hawkes","year":"2018","journal-title":"J\u00a0Immunol"},{"key":"2026041404120121900_ljad252-B10","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","article-title":"Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"2026041404120121900_ljad252-B11","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"2026041404120121900_ljad252-B12","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjd.19341","article-title":"Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy\u2013assessor-blinded clinical trial","volume":"184","author":"Warren","year":"2021","journal-title":"Br J Dermatol"},{"key":"2026041404120121900_ljad252-B13","author":"European Medicines Agency"},{"key":"2026041404120121900_ljad252-B14","author":"Amgen"},{"key":"2026041404120121900_ljad252-B15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jaad.2021.07.040","article-title":"Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial","volume":"86","author":"Stein Gold","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2026041404120121900_ljad252-B16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)","volume":"73","author":"Papp","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"2026041404120121900_ljad252-B17","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/bjd.14164","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)","volume":"173","author":"Paul","year":"2015","journal-title":"Br J Dermatol"},{"key":"2026041404120121900_ljad252-B18","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2147\/PPA.S85773","article-title":"Patient-reported treatment satisfaction and choice of dosing frequency with biologic treatment for moderate to severe plaque psoriasis","volume":"9","author":"Zhang","year":"2015","journal-title":"Patient Prefer Adher"},{"issue":"36","key":"2026041404120121900_ljad252-B19","article-title":"Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications","volume":"7","author":"Bharmal","year":"2009","journal-title":"Health Qual Life Outcomes"},{"key":"2026041404120121900_ljad252-B20"},{"key":"2026041404120121900_ljad252-B21","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/j.jid.2020.03.504","article-title":"The impact of psoriasis and its associated comorbidities on quality of life: Results from the National Psoriasis Foundation Annual Survey","volume":"140","author":"Bell","year":"2020","journal-title":"J Invest Dermatol"},{"key":"2026041404120121900_ljad252-B22","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1111\/bjd.20657","article-title":"Decreased quality of life in people with psoriasis and psoriatic arthritis vs. people with psoriasis alone: data from a national US survey","volume":"185","author":"Gondo","year":"2021","journal-title":"Br J Dermatol"},{"key":"2026041404120121900_ljad252-B23","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","article-title":"Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean?","volume":"125","author":"Hongbo","year":"2005","journal-title":"J Invest Dermatol"},{"key":"2026041404120121900_ljad252-B24","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/bjd.18798","article-title":"A multinational assessment of work-related productivity loss and indirect costs from a survey of patients with psoriasis","volume":"183","author":"Villacorta","year":"2020","journal-title":"Br J Dermatol"},{"key":"2026041404120121900_ljad252-B25","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/bjd.12039","article-title":"Adherence to medication in patients with psoriasis: a systematic literature review","volume":"168","author":"Thorneloe","year":"2013","journal-title":"Br J Dermatol"},{"key":"2026041404120121900_ljad252-B26","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s13555-017-0205-2","article-title":"Dermatologist and patient preferences in choosing treatments for moderate to severe psoriasis","volume":"7","author":"Alcusky","year":"2017","journal-title":"Dermatol Ther"},{"key":"2026041404120121900_ljad252-B27","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/jamadermatol.2020.0723","article-title":"Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis","volume":"156","author":"Blauvelt","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2026041404120121900_ljad252-B28","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1046\/j.1365-2710.1998.00181.x","article-title":"Quality of life measures in psoriasis: a critical appraisal of their quality","volume":"23","author":"Ashcroft","year":"1998","journal-title":"J Clin Pharm Ther"},{"key":"2026041404120121900_ljad252-B29","first-page":"859","article-title":"A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis","volume":"50","author":"Carlin","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"2026041404120121900_ljad252-B30","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2026041404120121900_ljad252-B31","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/jdv.12555","article-title":"A randomized, blinded assessor study to evaluate the efficacy and safety of etanercept 50\u2005mg once weekly plus as needed topical agent vs. etanercept 50\u2005mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE)","volume":"29","author":"Papp","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljad252\/51278907\/ljad252.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/189\/5\/540\/59959242\/ljad252.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/189\/5\/540\/59959242\/ljad252.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T08:12:17Z","timestamp":1776154337000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/189\/5\/540\/7227872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,25]]},"references-count":31,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,7,25]]},"published-print":{"date-parts":[[2023,10,25]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljad252","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11]]},"published":{"date-parts":[[2023,7,25]]}}}